160 related articles for article (PubMed ID: 34178428)
1. Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer.
Kol A; Lubbers JM; Terwindt ALJ; Workel HH; Plat A; Wisman GBA; Bart J; Nijman HW; De Bruyn M
Oncoimmunology; 2021 Jun; 10(1):1936391. PubMed ID: 34178428
[TBL] [Abstract][Full Text] [Related]
2. Association of homozygous variants of STING1 with outcome in human cervical cancer.
Lubbers JM; Koopman B; de Klerk-Sluis JM; van Rooij N; Plat A; Pijper H; Koopman T; van Hemel BM; Hollema H; Wisman B; Nijman HW; de Bruyn M
Cancer Sci; 2021 Jan; 112(1):61-71. PubMed ID: 33040406
[TBL] [Abstract][Full Text] [Related]
3. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.
Workel HH; Komdeur FL; Wouters MC; Plat A; Klip HG; Eggink FA; Wisman GB; Arts HJ; Oonk MH; Mourits MJ; Yigit R; Versluis M; Duiker EW; Hollema H; de Bruyn M; Nijman HW
Eur J Cancer; 2016 Jun; 60():1-11. PubMed ID: 27038842
[TBL] [Abstract][Full Text] [Related]
4. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.
Shi F; Su J; Wang J; Liu Z; Wang T
Mol Cell Biochem; 2021 Feb; 476(2):1015-1024. PubMed ID: 33141310
[TBL] [Abstract][Full Text] [Related]
5. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
[TBL] [Abstract][Full Text] [Related]
6. Cancer cell-intrinsic STING is associated with CD8 + T-cell infiltration and might serve as a potential immunotherapeutic target in hepatocellular carcinoma.
Zhang Y; Zhai Q; Feng X; Chen D; Lu Y; Hu J; Xie H; Zhou L; Wu J; Zheng S
Clin Transl Oncol; 2021 Jul; 23(7):1314-1324. PubMed ID: 33502741
[TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
8. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
[TBL] [Abstract][Full Text] [Related]
9. CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer.
Komdeur FL; Prins TM; van de Wall S; Plat A; Wisman GBA; Hollema H; Daemen T; Church DN; de Bruyn M; Nijman HW
Oncoimmunology; 2017; 6(9):e1338230. PubMed ID: 28932636
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of resident CD103
Hu W; Sun R; Chen L; Zheng X; Jiang J
Acta Histochem; 2019 Jul; 121(5):657-663. PubMed ID: 31153587
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
12. CD103
Corgnac S; Malenica I; Mezquita L; Auclin E; Voilin E; Kacher J; Halse H; Grynszpan L; Signolle N; Dayris T; Leclerc M; Droin N; de Montpréville V; Mercier O; Validire P; Scoazec JY; Massard C; Chouaib S; Planchard D; Adam J; Besse B; Mami-Chouaib F
Cell Rep Med; 2020 Oct; 1(7):100127. PubMed ID: 33205076
[TBL] [Abstract][Full Text] [Related]
13. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.
Webb JR; Wick DA; Nielsen JS; Tran E; Milne K; McMurtrie E; Nelson BH
Gynecol Oncol; 2010 Sep; 118(3):228-36. PubMed ID: 20541243
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral CD103-positive tumour-infiltrating lymphocytes are associated with favourable prognosis in patients with triple-negative breast cancer.
Park MH; Kwon SY; Choi JE; Gong G; Bae YK
Histopathology; 2020 Oct; 77(4):560-569. PubMed ID: 32333690
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of tumour-infiltrating CD103
Zhou Q; Ou Y; Dai X; Chen X; Wu S; Chen W; Hu M; Yang C; Zhang L; Jiang H
Br J Cancer; 2023 Apr; 128(8):1466-1477. PubMed ID: 36759726
[TBL] [Abstract][Full Text] [Related]
16. CD103+ tumor-resident CD8+ T cell numbers underlie improved patient survival in oropharyngeal squamous cell carcinoma.
Hewavisenti R; Ferguson A; Wang K; Jones D; Gebhardt T; Edwards J; Zhang M; Britton W; Yang J; Hong A; Palendira U
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32527931
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103
Li R; Liu H; Cao Y; Wang J; Chen Y; Qi Y; Lv K; Liu X; Yu K; Lin C; Zhang H; He H; Li H; Chen L; Shen Z; Qin J; Zhang W; Sun Y; Xu J
Br J Cancer; 2020 May; 122(10):1525-1534. PubMed ID: 32205862
[TBL] [Abstract][Full Text] [Related]
18. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of the prognostic value of cyclic GMP-AMP synthase-stimulator of interferon (cGAS-STING) related genes in gastric cancer.
Yang KS; Xu CQ; Lv J
Bioengineered; 2021 Dec; 12(1):1238-1250. PubMed ID: 33843442
[TBL] [Abstract][Full Text] [Related]
20. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
